Clinical Trial Update: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update describing the safety, tolerability, and exploratory efficacy of intrathecally delivered AMT-162 gene therapy in adults with S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMT-162

Snippet

Sponsor: UniQure Biopharma B.V. | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING